Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017–2024): a retrospective, multicentre cohort studyResearch in context

Summary: Background: UGT1A1 genotype-guided dosing reduces severe toxicity in UGT1A1 poor metaboliser (PM) patients treated with irinotecan. However, the impact of a dose reduction on survival remains unknown. This study evaluated whether upfront 30% dose reductions of irinotecan in UGT1A1 PMs affe...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Sofía L.J. Peeters, Niels Heersche, Doortje Böhm, Stefan Böhringer, Roselien Guiljam, Emma C. Hulshof, Femke M. de Man, Mirjam de With, Marije Joosse, Gysella Oomens, Qiong-Yi Wu, Aisha Osman, Sander Bins, Irene E.G. van Hellemond, Brigitte C.M. Haberkorn, Arjan J. Verschoor, Miriam L. Wumkes, Ron H.N. van Schaik, Anna M. Thijs, Hans Gelderblom, Henk-Jan Guchelaar, Ron H.J. Mathijssen, Maarten J. Deenen
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2026-05-01
Ráidu:	The Lancet Regional Health. Europe
Fáttát:	UGT1A1 Irinotecan Pharmacogenetics Precision dosing Colorectal cancer Pancreatic cancer
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2666776226000414
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!